Literature DB >> 23273517

Synthesis and biological evaluation of analogues of the kinase inhibitor nilotinib as Abl and Kit inhibitors.

Damien Y Duveau1, Xin Hu, Martin J Walsh, Suneet Shukla, Amanda P Skoumbourdis, Matthew B Boxer, Suresh V Ambudkar, Min Shen, Craig J Thomas.   

Abstract

The importance of the trifluoromethyl group in the polypharmacological profile of nilotinib was investigated. Molecular editing of nilotinib led to the design, synthesis and biological evaluation of analogues where the trifluoromethyl group was replaced by a proton, fluorine and a methyl group. While these analogues were less active than nilotinib toward Abl, their activity toward Kit was comparable, with the monofluorinated analogue being the most active. Docking of nilotinib and of analogues 2a-c to the binding pocket of Abl and of Kit showed that the lack of shape complementarity in Kit is compensated by the stabilizing effect from its juxtamembrane region. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23273517      PMCID: PMC3547291          DOI: 10.1016/j.bmcl.2012.11.111

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  15 in total

1.  Comprehensive analysis of kinase inhibitor selectivity.

Authors:  Mindy I Davis; Jeremy P Hunt; Sanna Herrgard; Pietro Ciceri; Lisa M Wodicka; Gabriel Pallares; Michael Hocker; Daniel K Treiber; Patrick P Zarrinkar
Journal:  Nat Biotechnol       Date:  2011-10-30       Impact factor: 54.908

2.  Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.

Authors:  Ellen Weisberg; Hwan Geun Choi; Arghya Ray; Rosemary Barrett; Jianming Zhang; Taebo Sim; Wenjun Zhou; Markus Seeliger; Michael Cameron; Mohammed Azam; Jonathan A Fletcher; Maria Debiec-Rychter; Mark Mayeda; Daisy Moreno; Andrew L Kung; Pasi Antero Janne; Roya Khosravi-Far; Junia V Melo; Paul W Manley; Sophia Adamia; Catherine Wu; Nathanael Gray; James D Griffin
Journal:  Blood       Date:  2010-03-18       Impact factor: 22.113

3.  4,7-Dimethoxy-1,10-phenanthroline: an excellent ligand for the Cu-catalyzed N-arylation of imidazoles.

Authors:  Ryan A Altman; Stephen L Buchwald
Journal:  Org Lett       Date:  2006-06-22       Impact factor: 6.005

Review 4.  Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor.

Authors:  Robert Roskoski
Journal:  Biochem Biophys Res Commun       Date:  2005-11-11       Impact factor: 3.575

Review 5.  Normal and oncogenic forms of the receptor tyrosine kinase kit.

Authors:  Johan Lennartsson; Tanya Jelacic; Diana Linnekin; R Shivakrupa
Journal:  Stem Cells       Date:  2005       Impact factor: 6.277

6.  Fluorine interactions at the thrombin active site: protein backbone fragments H-C(alpha)-C=O comprise a favorable C-F environment and interactions of C-F with electrophiles.

Authors:  Jacob A Olsen; David W Banner; Paul Seiler; Björn Wagner; Thomas Tschopp; Ulrike Obst-Sander; Manfred Kansy; Klaus Müller; François Diederich
Journal:  Chembiochem       Date:  2004-05-03       Impact factor: 3.164

7.  Structure of a c-kit product complex reveals the basis for kinase transactivation.

Authors:  Clifford D Mol; Kheng B Lim; Vandana Sridhar; Hua Zou; Ellen Y T Chien; Bi-Ching Sang; Jacek Nowakowski; Daniel B Kassel; Ciarán N Cronin; Duncan E McRee
Journal:  J Biol Chem       Date:  2003-06-24       Impact factor: 5.157

8.  Completely N1-selective palladium-catalyzed arylation of unsymmetric imidazoles: application to the synthesis of nilotinib.

Authors:  Satoshi Ueda; Mingjuan Su; Stephen L Buchwald
Journal:  J Am Chem Soc       Date:  2011-12-14       Impact factor: 15.419

Review 9.  AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL.

Authors:  E Weisberg; P Manley; J Mestan; S Cowan-Jacob; A Ray; J D Griffin
Journal:  Br J Cancer       Date:  2006-05-23       Impact factor: 7.640

10.  The stem cell factor-c-KIT pathway must be inhibited to enable apoptosis induced by BCR-ABL inhibitors in chronic myelogenous leukemia cells.

Authors:  F Belloc; K Airiau; M Jeanneteau; M Garcia; E Guérin; E Lippert; F Moreau-Gaudry; F-X Mahon
Journal:  Leukemia       Date:  2009-01-22       Impact factor: 11.528

View more
  5 in total

Review 1.  Dissecting fibrosis: therapeutic insights from the small-molecule toolbox.

Authors:  Carmel B Nanthakumar; Richard J D Hatley; Seble Lemma; Jack Gauldie; Richard P Marshall; Simon J F Macdonald
Journal:  Nat Rev Drug Discov       Date:  2015-09-04       Impact factor: 84.694

2.  Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.

Authors:  Jie Zhao; Haitian Quan; Yongping Xu; Xiangqian Kong; Lu Jin; Liguang Lou
Journal:  Cancer Sci       Date:  2014-01-04       Impact factor: 6.518

Review 3.  Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy.

Authors:  Federico Rossari; Filippo Minutolo; Enrico Orciuolo
Journal:  J Hematol Oncol       Date:  2018-06-20       Impact factor: 17.388

4.  BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language.

Authors:  Charles Tapley Hoyt; Daniel Domingo-Fernández; Martin Hofmann-Apitius
Journal:  Database (Oxford)       Date:  2018-01-01       Impact factor: 3.451

5.  Pharmacophore modeling of nilotinib as an inhibitor of ATP-binding cassette drug transporters and BCR-ABL kinase using a three-dimensional quantitative structure-activity relationship approach.

Authors:  Suneet Shukla; Abdul Kouanda; Latoya Silverton; Tanaji T Talele; Suresh V Ambudkar
Journal:  Mol Pharm       Date:  2014-06-05       Impact factor: 4.939

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.